Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 9/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 2/20 | 0.39 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18479912 | 0.94 | GPR84 (0.44) | GPR84ALDH1A1CYP2C19PKMCRBN | |
| SCHEMBL18475004 | 0.94 | GPR84 (0.44) | GPR84ALDH1A1CYP2C19PKMCRBN | |
| SCHEMBL22327126 | 0.94 | GPR84 (0.44) | GPR84ALDH1A1CYP2C19PKMCRBN | |
| SCHEMBL19187027 | 0.88 | CRBN (0.43) | GPR84ALDH1A1CYP2C19PKMCRBN | |
| SCHEMBL24023212 | 0.86 | PKM (0.42) | GPR84ALDH1A1CYP2C19PKMCRBN | |
| SCHEMBL23621035 | 0.84 | ALDH1A1 (0.54) | GPR84ALDH1A1CYP2C19PKMCRBN | |
| SCHEMBL26550500 | 0.79 | GPR84 (0.40) | GPR84ALDH1A1CYP2C19PKMHTT | |
| SCHEMBL24721804 | 0.76 | CYP2C19 (0.41) | GPR84ALDH1A1CYP2C19PKMHTT | |
| SCHEMBL26804984 | 0.76 | CYP2C19 (0.41) | GPR84ALDH1A1CYP2C19PKMHTT | |
| SCHEMBL4551699 | 0.76 | PKM (0.41) | GPR84ALDH1A1CYP2C19PKMCRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210205339-A1 | CYCLIC PHOSPHATE SUBSTITUTED NUCLEOSIDE DERIVATIVES FOR THE TREATMENT OF LIVER DISEASES | MSD INTERNATIONAL GMBH (CH) | 2021-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210205339-A1 | CYCLIC PHOSPHATE SUBSTITUTED NUCLEOSIDE DERIVATIVES FOR THE TREATMENT OF LIVER DISEASES | SLC10A1, PNP, PYGL | GPR84 1800/4885ALDH1A1 1448/4885CYP2C19 1031/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.